NK cells from pleural effusions are potent antitumor effector cells

European Journal of Immunology

Volumn 43, Issue 2, 2013, Pages 331-334

  Terme, Magali ^a   Fridman, Wolf Hervé ^b,c   Tartour, Eric ^a,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anergy; Immunotherapy; NK cell

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; CELL ISOLATION; CELL STIMULATION; CYTOTOXICITY; DOWN REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KILLER CELL; METASTASIS; NATURAL KILLER CELL; NOTE; PLEURA EFFUSION; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; NEOPLASMS; PLEURAL EFFUSION; RECEPTORS, CELL SURFACE;

EID: 84873709648     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201243264     Document Type: Note

References (32)

1. Kiessling, R., Klein, E. and Wigzell, H., "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975. 5: 112-117.
2. Andoniou, C. E., Coudert, J. D. and Degli-Esposti, M. A., Killers and beyond: NK-cell-mediated control of immune responses. Eur J Immunol. 2008. 38: 2938-2942.
3. Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N. and Zitvogel, L., Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008. 9: 486-494.
4. Diefenbach, A., Jensen, E. R., Jamieson, A. M. and Raulet, D. H., Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001. 413: 165-171.
5. Glas, R., Franksson, L., Une, C., Eloranta, M. L., Ohlen, C., Orn, A. and Karre, K., Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med. 2000. 191: 129-138.
6. Mocikat, R., Braumuller, H., Gumy, A., Egeter, O., Ziegler, H., Reusch, U., Bubeck, A. et al., Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003. 19: 561-569.
7. Imai, K., Matsuyama, S., Miyake, S., Suga, K. and Nakachi, K., Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000. 356: 1795-1799.
8. Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M. A., Vallejo, C., Martos, J. A. et al., The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997. 79: 2320-2328.
9. Villegas, F. R., Coca, S., Villarrubia, V. G., Jimenez, R., Chillon, M. J., Jareno, J., Zuil, M. et al., Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002. 35: 23-28.
10. Eckl, J., Buchner, A., Prinz, P. U., Riesenberg, R., Siegert, S. I., Kammerer, R., Nelson, P. J. et al., Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl). 2012. 90: 55-66.
11. Fridman, W. H., Galon, J., Pages, F., Tartour, E., Sautes-Fridman, C. and Kroemer, G., Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011. 71: 5601-5605.
12. Mamessier, E., Sylvain, A., Thibult, M. L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Goncalves, A. et al., Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011. 121: 3609-3622.
13. Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S. et al., IL-18 Induces PD-1-Dependent Immunosuppression in Cancer. Cancer Res. 2011. 71: 5393-5399.
14. Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F. et al., Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 2012. 72: 2757-2767.
15. Elkabets, M., Ribeiro, V. S., Dinarello, C. A., Ostrand-Rosenberg, S., Di Santo, J. P., Apte, R. N. and Vosshenrich, C. A., IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010. 40: 3347-3357.
16. Halama, N., Braun, M., Kahlert, C., Spille, A., Quack, C., Rahbari, N., Koch, M. et al., Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011. 17: 678-689.
17. Carrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., Ratto, G. B. et al., Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008. 112: 863-875.
18. Schleypen, J. S., Baur, N., Kammerer, R., Nelson, P. J., Rohrmann, K., Grone, E. F., Hohenfellner, M. et al., Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res. 2006. 12: 718-725.
19. Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., Andre, P. et al., Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011. 71: 5412-5422.
20. Lutgendorf, S. K., Sood, A. K., Anderson, B., McGinn, S., Maiseri, H., Dao, M., Sorosky, J. I. et al., Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005. 23: 7105-7113.
21. Jinushi, M., Takehara, T., Tatsumi, T., Hiramatsu, N., Sakamori, R., Yamaguchi, S. and Hayashi, N., Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol. 2005. 43: 1013-1020.
22. Sanchez, C. J., Le Treut, T., Boehrer, A., Knoblauch, B., Imbert, J., Olive, D. and Costello, R. T., Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother. 2011. 60: 1-13.
23. Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D. and Costello, R. T., Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007. 109: 323-330.
24. Szczepanski, M. J., Szajnik, M., Welsh, A., Foon, K. A., Whiteside, T. L. and Boyiadzis, M., Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother. 2010. 59: 73-79.
25. Vacca, P., Martini, S., Garelli, V., Passalacqua, G., Moretta, L. and Mingari, M. C., NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong anti-tumor activity on short-term IL-2 activation. Eur J Immunol. 2013. 43: 550-561.
26. Laurini, J. A., Garcia, A., Elsner, B., Bellotti, M. and Rescia, C., Relation between natural killer cells and neoplastic cells in serous fluids. Diagn Cytopathol. 2000. 22: 347-350.
27. Green, L. K. and Griffin, J., Increased natural killer cells in fluids. A new, sensitive means of detecting carcinoma. Acta Cytol. 1996. 40: 1240-1245.
28. Benson, D. M., Jr., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A. et al., The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010. 116: 2286-2294.
29. Titov, K. S., Kiselevskii, M. V., Demidov, L. V., Mikhailova, I. N., Shubina, I., Rodionova, L. M., Sinel'nikov, I. E. et al., Use of recombinant interleukin-2 for intrapleural therapy of tumor-associated pleurisy. Bull Exp Biol Med. 2009. 148: 794-796.
30. Elkadi, D., Wiernik, P. H. and Tong, T. R., Resolution of massive pleural effusion due to lymphoma with intrapleural interleukin-2. Am J Hematol. 2010. 85: 711-712.
31. Tartour, E., Mathiot, C. and Fridman, W. H., Current status of interleukin-2 therapy in cancer. Biomed Pharmacother. 1992. 46: 473-484.
32. Ni, J., Miller, M., Stojanovic, A., Garbi, N. and Cerwenka, A., Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012. 209: 2351-2365.